Belite Bio, Inc logo

Belite Bio, Inc

NASDAQ:BLTE

Overview | Financials
Company Name Belite Bio, Inc
Symbol BLTE
Currency USD
Price 48.2
Market Cap 1,475,515,704
Dividend Yield 0%
52-week-range 26.65 - 50.66
Industry Biotechnology
Sector Healthcare
CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.
Website https://belitebio.com

An error occurred while fetching data.

About Belite Bio, Inc

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the

Related Stocks

Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc.

GLUE

5.69 USD

Esperion Therapeutics, Inc. logo

Esperion Therapeutics, Inc.

ESPR

1.65 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

6.69 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

2.31 USD

Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

TYRA

20.59 USD

Inotiv, Inc. logo

Inotiv, Inc.

NOTV

1.34 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

71.25 USD

MeiraGTx Holdings plc logo

MeiraGTx Holdings plc

MGTX

3.88 USD

Viridian Therapeutics, Inc. logo

Viridian Therapeutics, Inc.

VRDN

14.09 USD

Financials

Numbers are in millions USD

Numbers are in millions USD